Glucocorticosteroid treatment of asthma

T R Bai, T R Bai

Abstract

Inhaled glucocorticoids are currently an important part of asthma management. There is no evidence that the more recently introduced inhaled agents, which have high topical activity and low systemic bioavailability, are unsafe at doses below 2000 micrograms/d. The choice of the delivery device for inhaled glucocorticosteroids is as important as the choice of the particular drug.

References

    1. Pharmacoeconomics. 1993 Mar;3(3):205-19
    1. Eur Respir J. 1994 Oct;7(10):1839-44
    1. Allergy. 1994 Dec;49(10):888-90
    1. Thorax. 1995 Apr;50(4):328-32
    1. Br Med J (Clin Res Ed). 1986 Apr 19;292(6527):1045-7
    1. Eur Respir J. 1988 Dec;1(10):883-9
    1. N Engl J Med. 1990 Oct 11;323(15):1033-9
    1. Thorax. 1991 Mar;46(3):160-4
    1. Eur J Clin Pharmacol. 1991;40(1):77-82
    1. Lancet. 1991 Nov 23;338(8778):1340
    1. Lancet. 1992 Jun 20;339(8808):1493-7
    1. JAMA. 1992 Dec 23-30;268(24):3462-4
    1. Lancet. 1993 Feb 6;341(8841):324-7
    1. Am Rev Respir Dis. 1993 May;147(5):1306-10
    1. Am Rev Respir Dis. 1993 Jun;147(6 Pt 2):S25-8
    1. Thorax. 1993 May;48(5):506-11
    1. Am Rev Respir Dis. 1993 Oct;148(4 Pt 2):S1-26
    1. Am Rev Respir Dis. 1993 Nov;148(5):1220-5
    1. Thorax. 1993 Oct;48(10):955-6
    1. Eur Respir J. 1994 Jan;7(1):69-73
    1. Lancet. 1994 Jul 23;344(8917):219-24
    1. N Engl J Med. 1994 Sep 15;331(11):700-5

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel